compel valuat setup head multipl
messag base inbound investor call revisit potenti
valuat scenario follow recent data updat gi
gu convers manag friday broader market sell-off see
note view setup trade ev/
vs xbi posit head multipl pipelin updat includ
ph front-lin renal cell carcinoma rcc front-lin
hepatocellular carcinoma believ share could potenti see
upsid bull-cas scenario believ bear case
price stock
buy rate pt pt consist attribut
revenu rcc mcrpc cometriq cotel
estim cash year addit opportun cabometyx well potenti
pipelin product candid repres upsid valuat current forecast
peak us product sale base-cas scenario attribut
rcc share rcc respect
attribut share respect po
attribut mcrpc share respect
po also assum cabometyx exclus last on-going ip
challeng see ip takeaway note confid abil settl disput
polymorph patent expir
share current trade bear scenario valuat commerci
ip risk price view assum zero cabometyx sale growth
rel sale well zero ex-u royalti growth
credit given polymorph patent sum-of-the-part dcf impli per
share price suggest hypothet bear case scenario larg price
current valuat bear case scenario account multipl sourc potenti
near-term upsid includ phase top-lin result
rcc phase interim result tecentriq rog-
sw phase interim result differenti
thyroid carcinoma potenti label extens opportun includ nsclc
think potenti success see preview statist analysi
could justifi potenti upsid per share potenti
upsid per share os think success endpoint
highli like view could justifi maintain current share per
manag rcc remain prefer tki choic rcc
suggest peak us sale scenario driven predominantli slow growth
market segment bull-cas scenario achiev statist
signific secondari os endpoint compar assum
cabometyx could captur peak share rcc result peak us sale
recent gi readout see gi note bode well
success chanc view could justifi potenti upsid per
share absenc success rcc growth mcrpc scenario
attribut po view could support market share
peak annual us revenu unlik view bear-cas
scenario fail model peak us revenu assum
share respect
page analyst certif import disclosur
prostat cancer opportun view partial de-risk follow
promis gu data link could justifi potenti upsid per
share absenc rcc growth post-novel hormon
therapi nht mcrpc attract opportun given movement nht earlier
stage diseas docetaxel remain current standard care believ
could captur mcrpc sale current assum po given data date
mcrpc cohort up-siz link later link pursuit
potenti acceler approv
potenti upsid per share rcc trial success valu
mcrpc includ expans opportun nsclc thyroid cancer
larg incid lung cancer broad use therapi
yet seen tecentriq data popul recal expand
nsclc cohort upon see initi sign activ link
expect read initi data sometim radioiodine-refractori differenti
thyroid carcinoma dtc repres anoth increment opportun believ
could increment coupl hundr million dollar top line sale minim
favor ip settlement mid-term anoth sourc potenti upsid view
see ip takeaway note august loss cabozantinib exclus line
composit matter patent expir repres unlik worst-cas
scenario view previous spoken patent attorney highlight
multipl potenti avenu defend polymorph patent patent expir
well likelihood near-term patent infring lawsuit
believ strong case notabl fact sue shortli receiv paragraph
iv notic management recent cite confid defend polymorph patent
well invest franchis prolong ip runway mind dinner meet
management
opportun recal next-gen multikinas inhibitor design
exhibit strength mitig potenti weak undergo phase
dose escal management previous highlight observ promis sign singl agent
activ dinner meet management move combin studi also
plan file potenti ind year inhibitor kinas inhibitor
recent spoke management note impact compani
oper far modest vast major staff work remot
skeleton crew select critic function facil secur etc ensur
continu oper management highlight preclin work tox studi
pre-formul perform extern thing move forward plan
clinic execut management mention trial enrol on-going slightli
reduc clip prior guidanc provid base strong progress
signific wiggl room expect result partner
link complet enrol also
continu enrol well management seen much slowdown
commerci side like compani switch virtual market
highlight miss face-to-fac interact huge deal given cabometyx
strong brand among gu oncologist regard suppli chain highlight safeti
stock cover scenario management view worri
modestli adjust estim account recent commentari see
management meet takeaway note around rcc market dynam maintain buy
pt model rcc market share line management recent
commentari view rcc split opdivo yervoy
mrk/pfe keytruda inlyta monotherapi tki half share
remain buy rate pt
page analyst certif import disclosur
valu inc per share use dcf-base valuat method valuat includ commerci
product cabometyx cometriq well probability-adjust cash flow deriv compani pipelin royalti
out-licens program use discount rate termin growth rate appli termin year post-assum
gener entri cabozantinib
risk rate valuat inc includ regulatori commerci setback potenti emerg new
competitor lower product sale expect
page analyst certif import disclosur
licens contract revenu
total cost expens
interest incom net
incom tax
guggenheim secur llc estim sec file
page analyst certif import disclosur
